PAMU
NPCE icon

Pictet Asset Management (UK)’s Neuropace NPCE Stock Holding History

Pictet Asset Management (UK)’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$11.6M Buy
+485,964
New +$11.3M 0.01% 649

Other funds holding NPCE

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Pictet Asset Management (UK)'s NPCE Position: Q2 2021 in Review

Pictet Asset Management (UK) opened a new position in Neuropace (NPCE) in Q2 2021: 485,964 shares worth $11.6M. The stake represents 0.01% of the portfolio and ranks #649 among its holdings.

44 funds tracked by Wall St. Rank hold NPCE as of Q2 2021.

  • Pictet Asset Management (UK) held 485,964 shares of Neuropace worth $11.6M as of Q2 2021.
  • Neuropace was a new Pictet Asset Management (UK) position in Q2 2021.
  • Neuropace made up 0.01% of Pictet Asset Management (UK)'s portfolio in Q2 2021, its #649 holding.
  • 44 funds tracked by Wall St. Rank held Neuropace as of Q2 2021.

Based on Pictet Asset Management (UK)'s 13F filing for Q2 2021, filed 16 Aug 2021.